Article
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.
Cancer research - 15 Mar 2016
Boussemart Lise, Girault Isabelle, Malka-Mahieu Hélène, Mateus Christine, Routier Emilie, Rubington Margot, Kamsu-Kom Nyam, Thomas Marina, Tomasic Gorana, Agoussi Sandrine, Breckler Marie, Laporte Mélanie, Lacroix Ludovic, Eggermont Alexander M, Cavalcanti Andrea, Grange Florent, Adam Julien, Vagner Stéphan, Robert Caroline
Abstract excerpt
BRAF inhibitors (BRAFi) elicit therapeutic responses in metastatic melanoma, but alarmingly, also induce the formation of secondary benign and malignant skin tumors. Here, we report the emergence and molecular characterization of 73 skin and extracutaneous tumors in 31 patients who underwent BRAFi therapy. The majority of patients presented with classic epidermal tumors such as verrucous papillomas,...
Topics
- Antineoplastic Agents
- Cell Line, Tumor
- Dimerization
- Genotype
- Humans
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Skin Neoplasms